Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants

CONTEXT: Familial partial lipodystrophy (FPLD) is most commonly caused by pathogenic variants in LMNA and PPARG. Leptin replacement with metreleptin has largely been studied in the LMNA group. OBJECTIVE: To understand the efficacy of metreleptin in PPARG vs LMNA pathogenic variants and investigate p...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Endocrinol Metab
Главные авторы: Sekizkardes, Hilal, Cochran, Elaine, Malandrino, Noemi, Garg, Abhimanyu, Brown, Rebecca J
Формат: Artigo
Язык:Inglês
Опубликовано: Endocrine Society 2019
Предметы:
Clinical Research Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6563798/
https://ncbi.nlm.nih.gov/pubmed/31194872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2018-02787
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы